Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen C Bain

Showing results (111-120 of 129) with videos related to

Pageof 13
Sort By:
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|April 5, 2024
SGLT2 Inhibitors - The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative ReviewSamuel Seidu, Vicki Alabraba, Sarah Davies, et al.
Diabetes Care|May 6, 2020
Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER TrialJohn B Buse, Stephen C Bain, Johannes F E Mann, et al.
Circulation|December 14, 2021
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADERAhmed M Shaman, Stephen C Bain, George L Bakris, et al.
Circulation|December 20, 2018
Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or StrokeSubodh Verma, Neil R Poulter, Deepak L Bhatt, et al.
The New England Journal of Medicine|September 17, 2016
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 DiabetesSteven P Marso, Stephen C Bain, Agostino Consoli, et al.
Diabetes, Obesity & Metabolism|July 9, 2019
Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trialCees J Tack, Stephan Jacob, Cyrus Desouza, et al.
The New England Journal of Medicine|June 12, 2019
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 DiabetesMansoor Husain, Andreas L Birkenfeld, Morten Donsmark, et al.
Journal of Diabetes Research|April 16, 2015
Changes in plasma levels of N-arachidonoyl ethanolamine and N-palmitoylethanolamine following bariatric surgery in morbidly obese females with impaired glucose homeostasisAkhila Mallipedhi, Sarah L Prior, Gareth Dunseath, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|January 26, 2022
Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney diseaseJanaka Karalliedde, Peter Winocour, Tahseen A Chowdhury, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|January 12, 2021
Association of British Clinical Diabetologists and Renal Association guidelines on the detection and management of diabetes post solid organ transplantationTahseen A Chowdhury, Mona Wahba, Ritwika Mallik, et al.
Pageof 13

Showing results (111-120 of 129) with videos related to

Sort By:
Pageof 13
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|April 5, 2024
SGLT2 Inhibitors - The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative ReviewSamuel Seidu, Vicki Alabraba, Sarah Davies, et al.
Diabetes Care|May 6, 2020
Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER TrialJohn B Buse, Stephen C Bain, Johannes F E Mann, et al.
Circulation|December 14, 2021
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADERAhmed M Shaman, Stephen C Bain, George L Bakris, et al.
Circulation|December 20, 2018
Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or StrokeSubodh Verma, Neil R Poulter, Deepak L Bhatt, et al.
The New England Journal of Medicine|September 17, 2016
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 DiabetesSteven P Marso, Stephen C Bain, Agostino Consoli, et al.
Diabetes, Obesity & Metabolism|July 9, 2019
Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trialCees J Tack, Stephan Jacob, Cyrus Desouza, et al.
The New England Journal of Medicine|June 12, 2019
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 DiabetesMansoor Husain, Andreas L Birkenfeld, Morten Donsmark, et al.
Journal of Diabetes Research|April 16, 2015
Changes in plasma levels of N-arachidonoyl ethanolamine and N-palmitoylethanolamine following bariatric surgery in morbidly obese females with impaired glucose homeostasisAkhila Mallipedhi, Sarah L Prior, Gareth Dunseath, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|January 26, 2022
Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney diseaseJanaka Karalliedde, Peter Winocour, Tahseen A Chowdhury, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|January 12, 2021
Association of British Clinical Diabetologists and Renal Association guidelines on the detection and management of diabetes post solid organ transplantationTahseen A Chowdhury, Mona Wahba, Ritwika Mallik, et al.
Pageof 13